Clovis Oncology Inc (CLVS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Clovis Oncology Inc (CLVS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9835
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company’s development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercializes rights for rociletinib, rucaparib and holds right in the US and Japan for lucitanib. Clovis has collaboration agreements with various companies such as Celgene Avilomics Research Inc.; Advenchen Laboratories LLC; Pfizer Inc. and Les Laboratoires Servier for the development and commercialization of its product candidates. The company operates offices in San Francisco and California, the US; Cambridge, the UK; and Milan, Italy. Clovis is headquartered in Boulder, Colorado, the US.

Clovis Oncology Inc (CLVS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Licensing Agreements 17
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Equity Offering 19
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For US$262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For US$75 Million 29
Debt Offering 31
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Acquisition 33
Clovis Oncology Acquires EOS For US$420 Million 33
Clovis Oncology Inc – Key Competitors 35
Clovis Oncology Inc – Key Employees 36
Clovis Oncology Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 30, 2018: Clovis Oncology announces third quarter 2018 operating results 38
Aug 01, 2018: Clovis Oncology announces second quarter 2018 operating results 41
May 08, 2018: Clovis Oncology Reports First Quarter 2018 Operating Results 44
Feb 26, 2018: Clovis Oncology Announces 2017 Financial Results 47
Nov 01, 2017: Clovis Oncology Announces Third Quarter 2017 Operating Results 50
Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 53
May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 56
Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 59
Corporate Communications 61
Oct 11, 2018: Clovis Oncology appoints two new Directors to its Board 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For US$262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For US$75 Million 29
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Clovis Oncology Acquires EOS For US$420 Million 33
Clovis Oncology Inc, Key Competitors 35
Clovis Oncology Inc, Key Employees 36
Clovis Oncology Inc, Other Locations 37
Clovis Oncology Inc, Subsidiaries 37

List of Figures
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Clovis Oncology Inc (CLVS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cowen Inc:企業の戦略・SWOT・財務情報
    Cowen Inc - Strategy, SWOT and Corporate Finance Report Summary Cowen Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Fcmb Group Plc:企業の戦略・SWOT・財務分析
    Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report Summary Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • AcuFocus Inc-医療機器分野:企業M&A・提携分析
    Summary AcuFocus Inc (AcuFocus) is a medical device company that develops and markets technologies for the improvement of near vision. The company's products include kamra inlay, small aperture lens and acutarget HD instrument. It offers near vision solutions and develops ophthalmic medical devices. …
  • Orsted AS (ORSTED):企業の財務・戦略的SWOT分析
    Orsted AS (ORSTED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Evoqua Water Technologies Corp (AQUA):電力:M&Aディール及び事業提携情報
    Summary Evoqua Water Technologies Corp (Evoqua) is a clean technology company that provides wastewater treatment systems and solutions. It offers various products such as activated carbons, systems for filtration, aeration and mixing, biological treatment, anaerobic digestion processes; and oil wate …
  • China High Speed Transmission Equipment Group Co Ltd (658):企業の財務・戦略的SWOT分析
    China High Speed Transmission Equipment Group Co Ltd (658) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa …
  • Bicycle Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company that develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to ide …
  • Nacco Industries Inc:企業の戦略・SWOT・財務情報
    Nacco Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Nacco Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Lycamobile UK Limited:企業の戦略的SWOT分析
    Lycamobile UK Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Nabors Industries Ltd (NBR):企業の財務・戦略的SWOT分析
    Nabors Industries Ltd (NBR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • NuGEN Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company offers DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DNA …
  • One Lambda Inc:医療機器:M&Aディール及び事業提携情報
    Summary One Lambda Inc (One Lambda), a subsidiary of Thermo Fisher Scientific Inc is a medical device manufacturing company that offers laboratory products. The company develops and distributes antibody detection products and histocompatibility typing tests. Its products include HLA testing reagents …
  • Ipsen Biopharmaceuticals Inc:企業の戦略的SWOT分析
    Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Carr’s Group Plc (CARR):企業の財務・戦略的SWOT分析
    Carr's Group Plc (CARR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • J. Front Retailing Co., Ltd.:戦略・SWOT・企業財務分析
    J. Front Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary J. Front Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • MedImmune LLC:企業の戦略的SWOT分析
    MedImmune LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • The Kyoto Hotel, Ltd.
    The Kyoto Hotel, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Kyoto Hotel, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Intercede Group plc (IGP):企業の財務・戦略的SWOT分析
    Intercede Group plc (IGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Guala Closures S.p.A.:企業の戦略・SWOT・財務情報
    Guala Closures S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Guala Closures S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PT Bank China Construction Bank Indonesia Tbk:企業の戦略・SWOT・財務分析
    PT Bank China Construction Bank Indonesia Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank China Construction Bank Indonesia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆